Clinical trials in vascular gene therapy: the missing piece of the puzzle.
OBJECTIVE
Vascular gene transfer provides unique opportunities for novel therapies for cardiovascular disease. To define the limitations and expectations of translating preclinical strategies to clinical therapy, the kinetics and extent of vascular transgene expression must be determined.


METHODS
Published clinical and preclinical studies of vascular gene transfer.


METHODS
Kinetics and extent of vascular transgene expression.


RESULTS
In spite of ongoing clinical studies in vascular gene transfer, data regarding the kinetics and extent of transgene expression are very limited.


CONCLUSIONS
For the efficient translation of preclinical to clinical vascular gene transfer studies, the kinetics and extent of transgene expression should be determined. Novel imaging technologies and unique clinical scenarios for obtaining tissue should be considered.
Simari
Robert D
RD
Division of Cardiovascular Diseases, Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA. simari.robert@mayo.edu
O'Brien
Timothy
T
D002318:Cardiovascular Diseases / Q000235:genetics / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods*; D015870:Gene Expression; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D016491:Peripheral Vascular Diseases / Q000235:genetics / Q000628:therapy*; D012107:Research Design